The European Medicines Agency will make an EU-level trial advice pilot a permanent option for drug sponsors. In a regulatory update, EMA confirmed that sponsors running studies in the European Union can continue to seek centralized regulator input after the pilot’s initial phase. The decision matters for development strategy because earlier guidance can affect study design consistency, submission readiness, and how sponsors manage cross-country operational complexity. The permanent framework also signals EMA’s intent to reduce friction in early clinical planning. For industry, the practical question becomes which sponsor types and therapeutic areas see the most value from the advice pathway, and whether the approach will extend beyond the initial pilot scope over time.